Alzheimer's Club

A forum for non-censored ideas, news, research and technology on Alzheimer's disease

Home | Archive | Menu | Media News: AD Cure | Treatment | Theories | ARF News | PubMed | About | Contacts


			_


							_

Alzheimer's cure: World General Media News Headlines

Alzheimer's treatment: World General Media News Headlines

Alzheimer theories: World General Media News Headlines

Alzheimer science professional news: Alzforum News & Views

November 20, 2005

Israeli company announces positive findings from first clinical trial in Alzheimer's patients

"Nov. 20 - Predix Pharmaceuticals, an Israeli drug discovery and development company, announced that PRX-03140, its highly selective, proprietary serotonin 4 (5-HT4) receptor agonist, showed the desired alterations in brain wave activity in patients with mild-to-moderate Alzheimer's disease and was well-tolerated in a recently completed 14-day Phase Ib clinical trial. "The results of this Phase Ib trial in patients with Alzheimer's disease suggest that PRX-03140 is stimulating the 5-HT4 receptor in the brain and is eliciting the desired effects on brain waves consistent with approved drugs for Alzheimer's disease," said Stephen Donahue, M.D., vice president of clinical and regulatory affairs. "The excellent tolerability profile of PRX-03140 at all doses studied, combined with these early indicators of activity, are exciting preliminary results and warrant further evaluation in a Phase II trial." Michael G. Kauffman, M.D., Ph.D., president and CEO of Predix, added, "We expect to initiate a Phase II dose-ranging trial in Alzheimer's disease patients early next year." In parallel with these clinical development efforts, several positive studies of PRX-03140 in key preclinical models for memory, cognition, and disease modification were the subject of four poster presentations at the 35th Annual Meeting of the Society for Neuroscience in Washington, D.C. last week."

Source: Israel21C. November 20-25, 2005 News [FullText]

0 Comments:

Latest PubMed 20 review articles on Alzheimer’s

Latest PubMed 20 research articles on Alzheimer’s amyloid

Latest PubMed 50 research titles on Alzheimer’s

AlzClub Lay and Science News content is under automatic continuous update. Please check back often or subscribe to news of interest using RSS feed buttons below. Also, please email to us your news terms suggestions
A semi-fiction mystery novel "The Alzheimer Code" is under preparation. In this book the death of the President of the United States of America is followed by his preventive anti-amyloid vaccination against Alzheimer's disease. At the same time and for the same reason, in his agony of death Editor-in-Chief of London-based Nature science journal recalls he in fact witnessed the corruption of Alzheimer's pseudo-science, brought to the community by a keen student. This is a story of a corrupted Harvard University professor, a research center co-director and a godfather of the international network of science criminals. Be the first to know when Alzheimer Code is published, by subscribing to an AlzClub.org news alerts . Otherwise automate your Alzheimer’s information portfolio with a number of options presented at this page.
Subscribe to AlzClub Mailing List, and freely share your information directly with your peers by e-mail. Click here to prepare email message requesting AlzClub Mailing List subscription
Would you like to author articles at Alzheimer's Club? Then send us your masterpiece, so we can screen it and publish at Alzclub.org. Please note that comments (on articles published previously) can be posted directly and anonymously (but why you would stay not known to the public?)
Do you know that as of May 3, 2005 NIH asks NIH-funded scientists to deposit their articles (published earlier in scientific journals) in PubMedCentral (PMC)? PMC is accessible to all for free and is one form of the academic world movement towards Public Open Access to scholar literature, free from commercial publishers' cabal. New to Open Access? Then you miss important science publishing development, because an NIH provision became a US law at the end of 2007. Read lay language article on Open Access authored by AlzClub founder. NIH-funded authors: visit the NIH Manuscript Submission system for more information.

AlzClub home
AlzClub: about
Become AlzClub author
Previous page
Important links
Career Resources
Alzheimer's must know
AlzForum Community
Conferences
Open Access (OA)
Recent content
Archive

AlzForum Members

AlzClub Mailing List

Researcher Profiles

Institutes/Labs

AlzClub is a not-for-profit forum for non-censored ideas, news, research, technology and clinics on Alzheimer's disease and related disorders. It is run by scientists for scientists, clinicians, patients, family members, care givers and all others interested in neurodegenerative diseases. AlzClub is founded and edited by Alexei Koudinov, MD, PhD, who is well known for his successful battle against the corruption of Alzheimer's field, ex. Open letter to President GW Bush, Correspondence with Wall Street Journal, Security and Exchange Commission (SEC) and others, Written Evidence to UK Parliament committee, AAAS Science publications, direct correspondence with Alzheimer's scientists, etc.

AlzClub home
Previous page
Helpful links
Career Resources
Open Access (OA)
Conferences
Recent content
Archive
____________
Back to the top

World General Media News on Alzheimer’s Cure
World General Media News on Alzheimer’s Treatment
World General Media News on Alzheimer’s Theories
Alzforum.org News: Alzheimer’s Research Forum News & Views
PubMed: Latest 20 review articles on Alzheimer’s
PubMed: Latest 20 articles on Alzheimer’s amyloid
PubMed: Latest 50 titles on Alzheimer’s disease
AlzClub Blog Posts XML
Alzclub Atom feed
Alternatively, please click feed buttom of your browser to identify (and consider subscribing to) a number of feeds that AlzClub offers


			_


							_